An Open-label, Phase II, Registry Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Subjects With Somatostatin Receptor Positive Tumours

Trial Profile

An Open-label, Phase II, Registry Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Subjects With Somatostatin Receptor Positive Tumours

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2015

At a glance

  • Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2021 to 1 Apr 2023.
    • 13 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2021 to 1 Apr 2023.
    • 13 Apr 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Sep 2021 to 1 Apr 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top